Oncomed Pharmaceuticals Inc (NASDAQ:OMED) stock price target increased to $20.00, issued a research note today by HC Wainwright
- Updated: September 22, 2016
In a report released on 9/22/2016 HC Wainwright increased the stock price target of Oncomed Pharmaceuticals Inc (NASDAQ:OMED) to $20.00 indicating a possible upside of 0.68%.
Previously on 04/12/2016, BMO Capital Markets reported on Oncomed Pharmaceuticals Inc (NASDAQ:OMED) increased the target price from $0.00 to $20.00. At the time, this indicated a possible upside of 0.92%.
Yesterday Oncomed Pharmaceuticals Inc (NASDAQ:OMED) traded 2.24% higher at $11.87. The company’s 50-day moving average is $11.08 and its 200-day moving average is $11.66. The last closing price is up 1.81% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 126,590 shares of the stock traded hands, down from an average trading volume of 208,331
See Chart Below
Oncomed Pharmaceuticals Inc has a 52 week low of $8.42 and a 52 week high of $23.98 The company’s market cap is currently $0.
In addition to HC Wainwright reporting its stock price target, a total of 6 brokers have issued a research note on the company. The average stock price target is $18.17 with 2 brokers rating the stock a strong buy, 3 brokers rating the stock a buy, 1 broker rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Oncomed Pharmaceuticals Inc (NASDAQ:OMED)
OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company's product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc. The Company's Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4), in the Notch signaling pathway. Tarextumab is an antibody that binds to both the Notch2 and Notch3 receptors. Ipafricept is the Company's Wnt pathway modulator. GITRL-Fc is a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor related protein.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.